All Oncology News

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Sac-TMT offered significant survival benefits vs docetaxel in pretreated EGFR-mutated NSCLC.

Neoadjuvant T-DXd followed by THP has received conditional approval in China for the treatment of patients with HER2-positive stage II/III breast cancer.

The EMA’s CHMP has recommended the approval of subcutaneous isatuximab via on-body injector for the treatment of multiple myeloma.

Subcutaneous daratumumab was approved in Europe for patient or caregiver administration in multiple myeloma.

PI3Kα inhibitor, risovalisib has been approved in Japan for PIK3CA-mutated ovarian clear cell carcinoma after progression on chemotherapy.

Theresa Guise, MD, and Stephanie S. Watowich, PhD, of The University of Texas MD Anderson Cancer Center, have been elected fellows of the American Association for the Advancement of Science.

Wendy Stock, MD, details key recommendations from the 2026 ASH guidelines for adolescent/young adult acute lymphoblastic leukemia management.

Zongertinib showed strong systemic and intracranial responses in HER2-mutant NSCLC with a manageable safety profile in Beamion LUNG-1.

Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC.

The ETOP ADEPPT trial met its primary end point with a 31% 12-week ORR with adagrasib in patients at least 70 years old with an ECOG PS of 0 or 1.

Real-world treatment with relugolix maintained QOL outcomes and had a manageable safety profile in patients with advanced prostate cancer.

Biomarker testing has added another layer to surgical planning in early-stage NSCLC, necessitating tighter multidisciplinary coordination.

Nodal clearance and pleural effusion after osimertinib induction were also identified as predictors of benefit with LCT in EGFR-mutated NSCLC.

Robert A. Winn, MD, has been named the next cancer center director for Fox Chase Cancer Center.

Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.

Jeffrey Zhong, MD, and Akshit Chitkara, MD, discuss 2 retrospective studies presented during the OncLive National Fellows Forum: Genitourinary Cancer.

Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC.

Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC.

Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.

R. Lor Randall, MD, FACS, highlights primary objectives of, and key takeaways from, the BOOM consensus meeting on PJI management in orthopedic oncology.

Megan Kruse, MD, discusses the use of imaging modalities in breast cancer management and emphasizes the role of FES-PET/CT in identifying ER presence.

The NCCN has added the IBCG risk stratification model for intermediate-risk NMIBC to its Clinical Practice Guidelines in Oncology for bladder cancer.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer.

Glofitamab combined with CAR T-cell therapy was associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Read on to see what abstracts experts in the field of lung cancer are interested in learning more about at ELCC 2026 in Copenhagen, Denmark.

Obe-cel was linked with durable survival outcomes in relapsed/refractory B-ALL, regardless of BOR of CR or CRi.

Study led by Roswell Park’s Dr. Brian Betts and Dr. Shernan Holtan highlighted in Blood Advances.